Stockreport

Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus [Yahoo! Finance]

Sana Biotechnology, Inc.  (SANA) 
PDF Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data i [Read more]